MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: A pooled analysis of four clinical trials
Monika E. Hegi*, Els Genbrugge, Thierry Gorlia, Roger Stupp, Mark R. Gilbert, Olivier L. Chinot, L. Burt Nabors, Greg Jones, Wim Van Criekinge, Josef Straub, Michael Weller
Dive into the research topics of 'MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: A pooled analysis of four clinical trials'. Together they form a unique fingerprint.